Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG

Sushmita Sinha, Sandhya Subramanian, Ashley Emerson-Webber, Maren Lindner, Gregory G. Burrows, Marjorie Grafe, Christopher Linington, Arthur Vandenbark, Claude C A Bernard, Halina Offner

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Increasing evidence suggests that in addition to T cell-dependent effector mechanisms, autoantibodies are also involved in the pathogenesis of MS, including demyelinating antibodies specific for myelin oligodendrocyte glycoprotein (MOG). Our previous studies have demonstrated that recombinant Tcell receptor ligands (RTLs) are very effective for treating T cell-mediated experimental autoimmune encephalomyelitis (EAE). In order to expand the scope of RTL therapy in MS patients, it was of interest to study RTL treatment of EAE involving a demyelinating antibody component. Therefore, we evaluated the therapeutic effects of RTL551, specific for T cells reactive to mouse (m)MOG-35-55 peptide, on EAE induced with recombinant human (rh)MOG in C57BL/6 mice. We report that RTL551 therapy can reverse disease progression and reduce demyelination and axonal damage induced by rhMOG without suppressing the anti-MOG antibody response. This result suggests that T cell-mediated inflammation and associated bloodbrain barrier dysfunction are the central contributors to EAE pathogenesis and that successful regulation of these key players restricts potential damage by demyelinating antibodies. The results of our study lend support for the use of RTL therapy for treatment of MS subjects whose disease includes inflammatory T cells as well as those with an additional antibody component.

Original languageEnglish (US)
Pages (from-to)231-239
Number of pages9
JournalJournal of NeuroImmune Pharmacology
Volume5
Issue number2
DOIs
StatePublished - Jun 2010

Fingerprint

Autoimmune Experimental Encephalomyelitis
Ligands
T-Lymphocytes
Myelin-Oligodendrocyte Glycoprotein
Antibodies
Therapeutics
Demyelinating Diseases
Therapeutic Uses
Inbred C57BL Mouse
Autoantibodies
Antibody Formation
Disease Progression
human MOG protein
Inflammation
Peptides

Keywords

  • CNS damage
  • EAE
  • MS
  • Recombinant human MOG

ASJC Scopus subject areas

  • Pharmacology
  • Immunology and Allergy
  • Immunology
  • Neuroscience (miscellaneous)

Cite this

Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. / Sinha, Sushmita; Subramanian, Sandhya; Emerson-Webber, Ashley; Lindner, Maren; Burrows, Gregory G.; Grafe, Marjorie; Linington, Christopher; Vandenbark, Arthur; Bernard, Claude C A; Offner, Halina.

In: Journal of NeuroImmune Pharmacology, Vol. 5, No. 2, 06.2010, p. 231-239.

Research output: Contribution to journalArticle

Sinha, Sushmita ; Subramanian, Sandhya ; Emerson-Webber, Ashley ; Lindner, Maren ; Burrows, Gregory G. ; Grafe, Marjorie ; Linington, Christopher ; Vandenbark, Arthur ; Bernard, Claude C A ; Offner, Halina. / Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. In: Journal of NeuroImmune Pharmacology. 2010 ; Vol. 5, No. 2. pp. 231-239.
@article{f613c2eaeaf14725b61804ac153b4524,
title = "Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG",
abstract = "Increasing evidence suggests that in addition to T cell-dependent effector mechanisms, autoantibodies are also involved in the pathogenesis of MS, including demyelinating antibodies specific for myelin oligodendrocyte glycoprotein (MOG). Our previous studies have demonstrated that recombinant Tcell receptor ligands (RTLs) are very effective for treating T cell-mediated experimental autoimmune encephalomyelitis (EAE). In order to expand the scope of RTL therapy in MS patients, it was of interest to study RTL treatment of EAE involving a demyelinating antibody component. Therefore, we evaluated the therapeutic effects of RTL551, specific for T cells reactive to mouse (m)MOG-35-55 peptide, on EAE induced with recombinant human (rh)MOG in C57BL/6 mice. We report that RTL551 therapy can reverse disease progression and reduce demyelination and axonal damage induced by rhMOG without suppressing the anti-MOG antibody response. This result suggests that T cell-mediated inflammation and associated bloodbrain barrier dysfunction are the central contributors to EAE pathogenesis and that successful regulation of these key players restricts potential damage by demyelinating antibodies. The results of our study lend support for the use of RTL therapy for treatment of MS subjects whose disease includes inflammatory T cells as well as those with an additional antibody component.",
keywords = "CNS damage, EAE, MS, Recombinant human MOG",
author = "Sushmita Sinha and Sandhya Subramanian and Ashley Emerson-Webber and Maren Lindner and Burrows, {Gregory G.} and Marjorie Grafe and Christopher Linington and Arthur Vandenbark and Bernard, {Claude C A} and Halina Offner",
year = "2010",
month = "6",
doi = "10.1007/s11481-009-9175-1",
language = "English (US)",
volume = "5",
pages = "231--239",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG

AU - Sinha, Sushmita

AU - Subramanian, Sandhya

AU - Emerson-Webber, Ashley

AU - Lindner, Maren

AU - Burrows, Gregory G.

AU - Grafe, Marjorie

AU - Linington, Christopher

AU - Vandenbark, Arthur

AU - Bernard, Claude C A

AU - Offner, Halina

PY - 2010/6

Y1 - 2010/6

N2 - Increasing evidence suggests that in addition to T cell-dependent effector mechanisms, autoantibodies are also involved in the pathogenesis of MS, including demyelinating antibodies specific for myelin oligodendrocyte glycoprotein (MOG). Our previous studies have demonstrated that recombinant Tcell receptor ligands (RTLs) are very effective for treating T cell-mediated experimental autoimmune encephalomyelitis (EAE). In order to expand the scope of RTL therapy in MS patients, it was of interest to study RTL treatment of EAE involving a demyelinating antibody component. Therefore, we evaluated the therapeutic effects of RTL551, specific for T cells reactive to mouse (m)MOG-35-55 peptide, on EAE induced with recombinant human (rh)MOG in C57BL/6 mice. We report that RTL551 therapy can reverse disease progression and reduce demyelination and axonal damage induced by rhMOG without suppressing the anti-MOG antibody response. This result suggests that T cell-mediated inflammation and associated bloodbrain barrier dysfunction are the central contributors to EAE pathogenesis and that successful regulation of these key players restricts potential damage by demyelinating antibodies. The results of our study lend support for the use of RTL therapy for treatment of MS subjects whose disease includes inflammatory T cells as well as those with an additional antibody component.

AB - Increasing evidence suggests that in addition to T cell-dependent effector mechanisms, autoantibodies are also involved in the pathogenesis of MS, including demyelinating antibodies specific for myelin oligodendrocyte glycoprotein (MOG). Our previous studies have demonstrated that recombinant Tcell receptor ligands (RTLs) are very effective for treating T cell-mediated experimental autoimmune encephalomyelitis (EAE). In order to expand the scope of RTL therapy in MS patients, it was of interest to study RTL treatment of EAE involving a demyelinating antibody component. Therefore, we evaluated the therapeutic effects of RTL551, specific for T cells reactive to mouse (m)MOG-35-55 peptide, on EAE induced with recombinant human (rh)MOG in C57BL/6 mice. We report that RTL551 therapy can reverse disease progression and reduce demyelination and axonal damage induced by rhMOG without suppressing the anti-MOG antibody response. This result suggests that T cell-mediated inflammation and associated bloodbrain barrier dysfunction are the central contributors to EAE pathogenesis and that successful regulation of these key players restricts potential damage by demyelinating antibodies. The results of our study lend support for the use of RTL therapy for treatment of MS subjects whose disease includes inflammatory T cells as well as those with an additional antibody component.

KW - CNS damage

KW - EAE

KW - MS

KW - Recombinant human MOG

UR - http://www.scopus.com/inward/record.url?scp=77954562729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954562729&partnerID=8YFLogxK

U2 - 10.1007/s11481-009-9175-1

DO - 10.1007/s11481-009-9175-1

M3 - Article

C2 - 19789980

AN - SCOPUS:77954562729

VL - 5

SP - 231

EP - 239

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 2

ER -